Tonix Pharmaceuticals Awarded Up to $34 Million U.S. Department of Defense Contract for Accelerated Development of Broad-Spectrum Antiviral Program

Company Overview - Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company focused on developing, licensing, and commercializing therapeutics for human diseases, particularly in central nervous system (CNS) disorders [2] - The company has a pipeline that includes product candidates for fibromyalgia, acute stress reaction, cocaine intoxication, organ transplant rejection, autoimmunity, and cancer [2] Recent Developments - Tonix has been awarded an Other Transaction Agreement (OTA) with the Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop broad-spectrum antiviral agents [13][18] - The funding aims to enhance the medical readiness of military personnel in biological threat environments and supports the company's antiviral discovery program [9][18] Product Pipeline - Tonix's priority is to submit a New Drug Application (NDA) for Tonmya (TNX-102 SL) in the second half of 2024, which has completed two statistically significant Phase 3 studies for fibromyalgia management [2][7] - The company is also developing TNX-1300 for cocaine intoxication and TNX-1500, a monoclonal antibody for preventing organ transplant rejection and treating autoimmune diseases [2] Research and Development Facilities - Tonix utilizes advanced research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility located in Frederick, Maryland [1] Strategic Focus - The company is focusing on optimizing its TNX-4200 program, which aims to develop an orally available CD45 antagonist with broad-spectrum efficacy against various viral families [5][18] - Tonix's approach includes leveraging previous research on phosphatase inhibitors to optimize lead compounds for therapeutic intervention against biothreat agents [18]